Shopping Cart 0
Cart Subtotal
AED 0

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 25690

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 38535
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Pipeline Review, H2 2018

Summary

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Rheumatoid Arthritis, Graft Versus Host Disease (GVHD), Multiple Sclerosis, Solid Tumor, Acute Renal Failure (ARF) (Acute Kidney Injury), B-Cell Chronic Lymphocytic Leukemia, Gastrointestinal Radiation Toxicity, Kidney Transplant Rejection, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Psoriatic Arthritis, Sepsis, Skin And Soft Tissue Infections, Stem Cell Transplantation and Uveitis.

The latest report T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Pipeline Review, H2 2018, outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)

- The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects

- The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Overview

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Companies Involved in Therapeutics Development

Atox Bio Ltd

Five Prime Therapeutics Inc

Imugene Ltd

Johnson & Johnson

TheraMAB LLC

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Drug Profiles

ALPN-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALPN-202-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FPT-155-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FR-104-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CD278, CD28 and HER2 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reltecimod sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAB-08-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD28 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Dormant Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Discontinued Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Product Development Milestones

Featured News & Press Releases

Oct 22, 2018: Alpine Immune Sciences lead program ALPN-101 demonstrates preclinical activity in inflammatory arthritis and neurological inflammation

Oct 04, 2018: Alpine Immune Sciences to Present at Society for Immunotherapy of Cancer 33rd Annual Meeting

Sep 25, 2018: Atox Bio announces Independent Safety Monitoring Committee recommendation to continue Phase 3 study of Reltecimod in necrotizing soft tissue infections

Sep 24, 2018: Alpine Immune Sciences Announces Upcoming Scientific Presentations

Sep 11, 2018: OSE Immunotherapeutics announces issuance of a European Patent protecting FR104, CD28-antagonist immunotherapy

Aug 22, 2018: OSE Immunotherapeutics publishes new efficacy data on FR104, CD28-antagonist immunotherapy

May 29, 2018: Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)

Apr 17, 2018: Alpine Immune Sciences announces preclinical data demonstrating ALPN-202 eliminates tumors and creates persistent tumor resistance in a murine cancer model

Dec 09, 2017: Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease

Dec 06, 2017: Alpine Immune Sciences Announces Preclinical Results Showing Novel Immuno-Oncology Co stimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells

Nov 06, 2017: Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation

Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155

Oct 19, 2017: OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 25, 2017: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Atox Bio Ltd, H2 2018

Pipeline by Five Prime Therapeutics Inc, H2 2018

Pipeline by Imugene Ltd, H2 2018

Pipeline by Johnson & Johnson, H2 2018

Pipeline by TheraMAB LLC, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Therapeutic Products under Development, Key Players in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Therapeutics, T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Pipeline Overview, T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Pipeline, T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Pipeline Assessment


Companies

Atox Bio Ltd

Five Prime Therapeutics Inc

Imugene Ltd

Johnson & Johnson

TheraMAB LLC

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Pipeline Review, H2 2018

Summary

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Rheumatoid Arthritis, Graft Versus Host Disease (GVHD), Multiple Sclerosis, Solid Tumor, Acute Renal Failure (ARF) (Acute Kidney Injury), B-Cell Chronic Lymphocytic Leukemia, Gastrointestinal Radiation Toxicity, Kidney Transplant Rejection, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Psoriatic Arthritis, Sepsis, Skin And Soft Tissue Infections, Stem Cell Transplantation and Uveitis.

The latest report T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Pipeline Review, H2 2018, outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)

- The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects

- The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Overview

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Companies Involved in Therapeutics Development

Atox Bio Ltd

Five Prime Therapeutics Inc

Imugene Ltd

Johnson & Johnson

TheraMAB LLC

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Drug Profiles

ALPN-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALPN-202-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FPT-155-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FR-104-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CD278, CD28 and HER2 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reltecimod sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAB-08-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD28 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Dormant Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Discontinued Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)-Product Development Milestones

Featured News & Press Releases

Oct 22, 2018: Alpine Immune Sciences lead program ALPN-101 demonstrates preclinical activity in inflammatory arthritis and neurological inflammation

Oct 04, 2018: Alpine Immune Sciences to Present at Society for Immunotherapy of Cancer 33rd Annual Meeting

Sep 25, 2018: Atox Bio announces Independent Safety Monitoring Committee recommendation to continue Phase 3 study of Reltecimod in necrotizing soft tissue infections

Sep 24, 2018: Alpine Immune Sciences Announces Upcoming Scientific Presentations

Sep 11, 2018: OSE Immunotherapeutics announces issuance of a European Patent protecting FR104, CD28-antagonist immunotherapy

Aug 22, 2018: OSE Immunotherapeutics publishes new efficacy data on FR104, CD28-antagonist immunotherapy

May 29, 2018: Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)

Apr 17, 2018: Alpine Immune Sciences announces preclinical data demonstrating ALPN-202 eliminates tumors and creates persistent tumor resistance in a murine cancer model

Dec 09, 2017: Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease

Dec 06, 2017: Alpine Immune Sciences Announces Preclinical Results Showing Novel Immuno-Oncology Co stimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells

Nov 06, 2017: Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation

Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155

Oct 19, 2017: OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 25, 2017: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Atox Bio Ltd, H2 2018

Pipeline by Five Prime Therapeutics Inc, H2 2018

Pipeline by Imugene Ltd, H2 2018

Pipeline by Johnson & Johnson, H2 2018

Pipeline by TheraMAB LLC, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Therapeutic Products under Development, Key Players in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Therapeutics, T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Pipeline Overview, T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Pipeline, T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Pipeline Assessment


Companies

Atox Bio Ltd

Five Prime Therapeutics Inc

Imugene Ltd

Johnson & Johnson

TheraMAB LLC